GSK Corporate Governance: Addressing Modern Slavery Risks in Global Supply Chains
GSK plc, a global biopharmaceutical company headquartered in London, maintains a public commitment to identifying and mitigating risks of modern slavery and human trafficking within its operations and supply chains. In accordance with the UK Modern Slavery Act 2015, the company publishes annual statements detailing the due diligence processes and governance structures it employs to ensure ethical labor practices across its international network.
How GSK Monitors Supply Chain Labor Risks
GSK utilizes a multi-layered risk management framework to oversee its global supply chain, which spans thousands of suppliers across various jurisdictions. According to the company’s official modern slavery disclosures, the firm mandates that all suppliers adhere to its “Responsible Sourcing Code.” This code establishes clear expectations regarding labor standards, including the prohibition of forced, bonded, or compulsory labor and the restriction of child labor.
To verify compliance, the company conducts risk assessments that categorize suppliers based on geographical location, industry sector, and spend volume. High-risk suppliers are subject to third-party audits and direct engagement to address potential non-compliance. These assessments are designed to align with the International Labour Organization (ILO) standards, which provide the global benchmark for identifying indicators of forced labor, such as the retention of identity documents or excessive recruitment fees.
Regulatory Requirements and Corporate Accountability
The UK Modern Slavery Act requires large commercial organizations carrying on business in the UK to produce an annual statement outlining the steps taken to ensure slavery and human trafficking are not present in their business or supply chains. This legislative requirement serves as a transparency mechanism, forcing companies to disclose their internal policies, due diligence procedures, and training programs.
While the act does not explicitly penalize the presence of slavery within a supply chain, it mandates public accountability. If a company fails to produce a statement, the Secretary of State may seek an injunction through the High Court to enforce compliance. GSK’s governance structure involves board-level oversight, ensuring that modern slavery risks are integrated into the company’s broader enterprise risk management strategy.
Comparison of Corporate Due Diligence Standards
Corporate approaches to human rights due diligence vary across the pharmaceutical industry, often depending on the regulatory environment of the company’s home country. The following table contrasts the primary mechanisms used by major pharmaceutical firms to address supply chain risks:
| Mechanism | GSK Approach | Industry Standard (General) |
|---|---|---|
| Primary Policy | Responsible Sourcing Code | Supplier Code of Conduct |
| Audit Basis | Risk-based (Geo/Sector) | Scheduled/Random Audits |
| Governance | Board-level oversight | Sustainability/Ethics Committee |
What Happens When Risks Are Identified?
When an audit or a report identifies potential labor violations, GSK’s policy is to prioritize remediation over immediate termination of the supplier relationship. This approach, often referred to as “remedial engagement,” aims to improve the supplier’s working conditions through corrective action plans. According to the company, if a supplier refuses to engage or fails to make significant improvements within a specified timeframe, the company reserves the right to terminate the contract.
This strategy reflects a broader shift in multinational corporate governance, moving away from purely defensive compliance toward active capacity building. By providing training to suppliers on local labor laws and international human rights standards, companies attempt to address the root causes of exploitation rather than simply shifting the problem to another supplier.
Key Takeaways
- Legal Mandate: GSK operates under the UK Modern Slavery Act 2015, which requires annual transparency regarding supply chain labor practices.
- Risk-Based Oversight: The company uses geographical and sectoral risk assessments to prioritize audit resources.
- Remediation Strategy: The primary goal of identifying non-compliance is to force corrective action rather than immediate contract termination, unless the supplier fails to improve.
- Global Standards: Policies are benchmarked against ILO conventions to ensure consistency across international operations.
As regulatory scrutiny continues to intensify globally, including the introduction of the EU Corporate Sustainability Due Diligence Directive, companies like GSK are expected to move toward even more granular reporting on their tier-two and tier-three suppliers. Future governance will likely require greater transparency regarding the efficacy of these remediation programs in protecting vulnerable workers.